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CASE REPORT
The Use of Cultured Allogenic Keratinocyte Grafting in 
a Patient with Epidermolysis Bullosa Simplex
Kee Cheol Shin, M.D., Bo Young Park, M.D., Han Koo Kim, M.D., Ph.D., 
Woo Seob Kim, M.D., Ph.D., Tae Hui Bae, M.D., Ph.D.
Department of Plastic and Reconstructive Surgery, Chung-Ang University Hospital, Seoul, Korea
Epidermolysis bullosa (EB) is a rare genetic disease that is 
known for continuous skin blistering caused by minor 
trauma. The skin blisters and bullae that develop often cause 
skin defects. There is no definitive treatment for EB, only 
symptomatic relief. We report our experience with cultured 
allogenic keratinocyte grafting in a newborn patient with EB 
simplex who had unhealed raw surfaces and was not a skin 
grafting candidate. The skin lesions of the patient were 
covered with cultured allogenic keratinocyte grafts and 
re-epithelialized quickly with no scarring. Allogenic kera-
tinocyte grafting reduced pain and produced noticeable 
improvements in the unhealed wounds. We think that 
allogenic keratinocyte grafting can play an important role in 
the management of patients with EB simplex. (Ann Dermatol 
23(S3) S393∼S397, 2011)
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INTRODUCTION
Epidermolysis bullosa (EB) is a rare genetic disease that 
manifests with blistering of the skin and mucous mem-
branes following minor mechanical trauma
1. Three major 
forms of EB have been defined using clinical and histo-
logical criteria. The simplex, junctional, and dystrophic 
forms of EB are characterized by loss of tissue integrity in 
the epidermis, at the lamina lucida or central basement 
membrane zone, and at the sub-lamina densa basement 
membrane
2. In most cases, EB simplex is inherited in an 
autosomal dominant pattern. EB simplex is the most com-
mon type of EB, with a prevalence of approximately 1 
case per 25,000 live births
3. 
The skin blisters and bullae that continuously develop in 
EB often lead to skin defects. Unhealed skin wounds lead 
to chronic wounds, which can give rise to squamous cell 
carcinoma. EB can also cause mucosal lesions, eye pro-
blems, dental problems, esophageal strictures, dysphagia, 
malabsorption, and many other complications. 
No specific treatment is available for EB; therefore, con-
servative management is the mainstay treatment. Wound 
healing in patients with EB is challenging. An ideal dres-
sing has not been developed, though there are a variety of 
suitable dressings available.
Cultured allogenic keratinocyte grafting has had encou-
raging results in burn patients. This prompted our interest 
in using it to manage patients with EB simplex.
We report our clinical experience with cultured allogenic 
keratinocyte grafting in a newborn patient with EB simplex 
who had unhealed, open 3×5 cm skin lesions and could 
not receive a skin graft. 
CASE REPORT
The patient, a 0-day-old boy, was immediately referred 
from a local clinic at birth due to multiple blisters on both 
feet and a wide range of skin defects. The skin defects 
were particularly serious on the inner surface of both feet, 
measured about 3×5 cm each, and displayed ongoing 
bleeding (Fig. 1). The patient’s father had been diagnosed KC Shin, et al
S394 Ann Dermatol
Fig. 1. (A) Bleeding lesions (3×5 cm)
on both feet of a 1 day-old boy who 
presented immediately after birth. (B) 
The medial aspects of both feet on 
post-birth day 12. (C) Epitheliali-
zation of the wounds on post- 
Kalloderm
Ⓡ application day 7.
Fig. 2. Loss of epidermal integrity occurred near the keratinocyte
basal layer, which is the defining characteristic of epidermolysis
bullosa simplex (H&E, ×400).
with EB simplex. However, he had improved with treat-
ment and had no active skin lesions. On admission, a skin 
biopsy with an electromicroscopic examination and immu-
nohistochemistry staining for cytokeratin K903 was per-
formed, and the patient was diagnosed with EB simplex, 
whichshowed suprabasal separation on an electromicro-
scopic examination of the biopsy (Fig. 2).
He was treated with non-adhesive foam dressing materials 
and antibiotic ointments until post-birth day 12. However, 
the skin defects at birth had not epithelialized at all by day 
12, and it was difficult to maintain the dressing materials 
given his movement. New blisters and bullae appeared 
secondary to mild constant irritation from the dressing 
materials, and the lesions enlarged and continuously bled 
(Fig. 1). Blisters and bullae also developed on the trunk, in 
the oral cavity, and on the limbs. Skin grafting could not 
be performed given the patient’s age and disease charac-
teristics. Thus, we considered allogenic keratinocyte graf-
ting to promote re-epithelialization. 
Kaloderm
Ⓡ (Tego Science, Seoul, Korea), which is cul-
tured allogenic keratinocytes, is a biologic dressing ma-The Use of Cultured Allogenic Keratinocyte Grafting in a Patient with Epidermolysis Bullosa Simplex
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Fig. 3. The wounds were covered with Kalloderm
Ⓡ  and petro-
leum roll gauze to reduce tissue trauma.
terial sheet derived from neonatal cultured forehead skin 
cells, which contains abundant growth factors and cyto-
kines, and has been used to promote re-epithelialization 
and pain relief for second-degree burns and diabetic foot 
wounds. 
We applied cultured allogenic keratinocyte grafts to the 
3×5 cm non-epithelialized lesions on both feet at post- 
birth day 12 and replaced them twice at 1 week intervals 
without using fixation sutures. Dressings that covered the 
cultured allogenic keratinocyte grafts were changed daily. 
These overlying dressings were not fixed, so they were 
covered with petroleum roll gauze and sterile towels to 
reduce tissue trauma (Fig. 3).
Skin defects were reduced by one half, and rapid re- 
epithelialization was confirmed on post-graft application 
day 7 (Fig. 1). Except for recurrent blisters, nearly total 
epithelialization was achieved on post-graft application 
day 14. The patient was discharged about 3 weeks after 
allogenic keratinocyte grafting, and skin lesions still 
occurred and were treated with ongoing dressings, but the 
skin defects had improved from the defects present at 
birth, and total epithelialization was well-maintained on 
the graft sites without any lesions.
DISCUSSION
EB is a group of inherited skin diseases characterized by 
trauma-induced bullae formation. Two main approaches 
can be attempted to modify wound healing in a patients 
with EB. One is to influence the inherent underlying 
abnormality and the other is to accelerate keratinocyte 
migration as quickly as possible.  
Symptomatic treatment is needed to manage the skin, 
respiratory, gastrointestinal, and genitourinary systems. 
Management involves wound care, including lancing of 
blisters to prevent spread, and sterile dressings
4. Nutri-
tional support is important to promote wound healing. 
Wounds in patients with EB occur as blisters or bullae. It 
is sometimes necessary to puncture the blister or bullae 
with a sterile needle to drain the fluid to prevent exten-
sion. Overlying skin should never be removed, as it acts 
as a biologic dressing and aides wound healing
5. 
Topical antibiotics should be used for short periods of 
time because of problems with antimicrobial resistance
6. 
Non-adhesive foam dressings are recommended to opti-
mize wound healing. The ideal dressing for managing EB 
has not been developed, although various dressings have 
been tried. Patients with EB are often unable to undergo 
surgery for skin grafting due to their age and disease 
characteristics. Therefore, patients with EB are treated 
conservatively in most cases. The recent development of 
bioengineered skin products has had a positive effect on 
wound healing in patients with EB. Treatment of difficult 
wounds in patients with EB may involve artificial skin 
substitutes such as dermal allografts, living bi-layered skin 
equivalents (e.g., Apligraft), biologic dressings (amniotic 
membrane grafting), and growth factors such as platelet 
derived growth factor
7. Williamson et al. reported that per-
sistent wounds were treated with Dermagraft, a fibroblast- 
derived skin substitute, resulting in 20∼100% epidermal 
coverage after 8 weeks in patients with epidermolysis 
bullosa dystrophica (DEB)
7. In another report, an amniotic 
membrane was applied to nonhealing ulcers in three 
patients with DEB, and all experienced significant pain 
relief and developed granulation tissue within 3 days of 
the application
8. Protein therapy, in which the missing or 
defective protein in patients with EB is produced in vitro 
using recombinant technology and applied directly to the 
affected skin, stem cell therapy, and gene therapy to 
restore normal protein production of specific structural 
proteins are new emerging treatments for EB
9. However, 
these new advancements are in their initial stages, and 
more research into the safety and efficacy of these treat-
ments is needed before clinical application. 
The age of onset in epidermolysis bullosa simplex (EBS) is 
variable, with most cases manifesting at birth. Severe 
cases of EBS require operative management. Surgery is 
difficult to perform, because a skin graft makes an 
additional wound at the donor site characteristic of the 
disease. In this study, we managed the wounds of a 
patient with EB with cultured allogenic keratinocyte 
grafting, which did not require suture fixation. 
Keratinocytes are abundant in the epidermis and are 
critical during the wound healing process. During normal 
wound healing, keratinocytes go to the wound base, 
differentiate from the basement membrane, and promote KC Shin, et al
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re-epithelialization. If the keratinocytes are abnormal, the 
wound healing process will be delayed. 
In 1975, Rheinwald and Green developed a culture te-
chnique to obtain a large quantity of cultured cells from 
small tissues
10. Since then, O'Connor et al. attempted cli-
nical human transplants and obtained successful results
11. 
Culturing autogenic keratinocytes requires 2∼3 weeks but 
proliferative capacity degrades in older patients with EB. 
Therefore, allogenic keratinocyte culture techniques were 
studied beginning in the late 1980s, and cultured allo-
genic keratinocyte materials were developed. Autogenic 
keratinocytes are exposed directly to the wound bed, 
epithelialize, and become permanent, whereas allogenic 
keratinocytes occur at the wound bed temporarily and are 
replaced by growth and migration of the remaining kera-
tinocytes from the wound periphery
12,13. The exact wound 
healing mechanism of allogenic keratinocytes is unknown. 
It is possible that growth factors and cytokines, which are 
expressed and secreted in cultured allogenic keratino-
cytes, promote cell proliferation, migration, and create 
basement membrane components that effect cellular 
engraftment and ultimately facilitate re-epithelialization. 
The representative cytokines are erythroid associated 
factor/interleukin (IL)-1αβ, IL-6, transforming growth 
factor-αβ, and epidermal growth factor. Platelet derived 
growth factor, insulin-like growth factor, and fibroblast 
growth factor are secreted and accelerate wound epithelia-
lization
14-16. Similar to a membrane, cultured allogenic 
keratinocytes in the form of a dressing material prevent 
leakage of water from the wound and maintain homeo-
stasis.
Cultured allogenic keratinocyte sheets are effective for 
diabetic foot wounds and second-degree or higher burns, 
and no reports of rejection have appeared. Despite these 
advantages, allogenic keratinocyte sheets do not absorb 
exudates and are still relatively expensive. Therefore, they 
have not been widely used. 
The raw surface of our patient with EB simplex was 
covered with thawed cultured allogenic keratinocyte graf-
ting sheets that were held in place with petroleum roll 
gauze and sterile surgical towel dressings. Skin defects 
were reduced by one half, and rapid re-epithelization was 
confirmed on post-graft application day 7. With the excep-
tion of recurrent bullae, nearly total epithelialization was 
achieved on post-graft application day 14. The use of al-
logenic keratinocyte grafting sheets in patients with EB 
presents these advantages: 1) they do not require skin 
grafts; thus, reducing surgical trauma; 2) they release 
various cytokines and growth factors that promote 
spontaneous rapid re-epithelialization; 3) they can relieve 
pain; 4) they require no anesthesia during application; 5) 
additional suture fixation is not needed; 6) they are very 
simple to use, just like a dressing material; and 7) no 
rejection response has been demonstrated.
In conclusion, allogenic keratinocyte grafting produced a 
noticeable improvement in the unhealed wounds of our 
patient with EB simplex by reducing trauma, and suppor-
ting epithelialization. We believe that allogenic keratino-
cyte grafting can play an important role in the conser-
vative management of EB simplex.
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